A Milestone Achievement: Ponte Biosciences Secures $20,000 in Non-Dilutive Funding
We are thrilled to announce that Ponte Biosciences, a subsidiary of Cytotheryx, emerged as the grand prize winner at the inaugural Avio Medtech Consulting pitch competition during the 23rd Annual Medtech MVP event in Minneapolis. This recognition comes with a $20,000 non-dilutive funding award, a boost for our work in developing life-saving technology for patients with acute liver failure.
Event Highlights
Date: This week, at the 23rd Annual Medtech MVP Event
Award: $20,000 non-dilutive funding
Our Journey and Competitors
We had the honor of pitching alongside two remarkable companies, Heart Failure Solutions and Sparta Biomedical, both of which are making strides in groundbreaking medical technologies. This experience was a testament to the collaborative and innovative spirit within the medtech community.
Acknowledgements
We extend our heartfelt thanks to the judges—Morgan Evans, Stephen Daley, and Amrinder Singh—and the entire Avio Medtech Consulting team. Special thanks also go to Mykel Pennington, Amy Langer, Julie Pritchard-Hedtke, and our pitch contest sponsors, Destination Medical Center (DMC), Fredrikson & Byron, P.A., and Mobius Medical, for their support and for making this event possible.
Looking Ahead
This victory marks an exciting chapter for Ponte Biosciences as we advance our bioartificial liver assist device towards the clinic. We are committed to continuing to advance medical technology to improve patient outcomes.
Stay tuned for more updates as we continue our mission to bring transformative solutions to the field of liver health.
